Journal

Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application.

Read time: 1 mins

Published:31st Jul 2019

Author: Sun H, Wu YL.

Source: Future Oncology

Availability: Pay for access, or by subscription

Ref.:Future Oncol. 2019;15(23):2769-2777.

DOI:10.2217/fon-2018-0535

Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application

Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor (TKI) that irreversibly binds to and inhibits EGFR/Her1, Her2 and Her4 subtypes with an efficacy comparable to other TKIs. In the ARCHER 1050 trial, progression-free survival was improved by dacomitinib compared with gefitinib, supporting dacomitinib as a first-line treatment option for advanced non-small-cell lung cancer with sensitive EGFR mutation. Regarding to the higher adverse events rate, dose reductions did not reduce the efficacy of dacomitinib and could effectively decreased the incidence and severity of adverse events. Considering the evolving landscape of EGFR-mutant non-small-cell lung cancer, future head to head comparison between dacomitinib and osimertinib could provide key information to determine the optimal TKI treatment schedule.

Read abstract on library site Access full article